News

Han discusses late-breaking phase 2 VIBRANT data at AAAAI 2026, which showed that quarterly TSLP receptor blockade reduced the need for CRSwNP by 76%.

The nephrology field continued to see advances in February 2026, with 5 headlines clincians may have missed.

Gu explains how addiction drives GI and liver disease and why integrated care is key to improving outcomes and survival.

Barzolvolimab therapy resulted in significant improvement of cold urticaria (ColdU) following 20 weeks of treatment.

Pooled REMIX-1/-2 data show remibrutinib reduced CSU activity within 12 hours, with greater UAS improvements vs placebo through day 7.

This World Obesity Day, catch up on major paradigm shifts in the diagnosis, discussion, and treatment of obesity, one of the world’s most devastating chronic diseases.

In this February review of the most significant developments in dermatology, the month’s most notable coverage of disease states such as psoriasis and atopic dermatitis is highlighted.

Cogent Biosciences previously submitted an NDA for bezuclastinib at the end of 2025.

Nadkarni’s research suggests LLMs often pass along medical misinformation, underscoring the need for oversight, evaluation, and stronger AI guardrails.

Catch up with FDA decisions, key trial results, podcast updates, and more.

Lyskjaer walks clinicians through 10-year data from a nationwide cohort study comparing ablation and surgery for renal cancer.

This segment of the February episode of The Medical Sisterhood podcast highlights burdens faced by those balancing motherhood with being a physician.

Catch up on durability data and real-world insight from trials across inflammatory bowel disease and short bowel syndrome.

Akin discussed how avapritinib continues to demonstrate its benefit in indolent systematic mastocytosis.

In February 2026, rusfertide garnered priority review, ASH published new guidelines, and luspatercept mets its primary endpoint in a phase 2a trial.

Norouzi discusses a recent review where 11 clinicians described C3G pathology and diagnosis.

At AAAAI 2026, Han reports pooled ANCHOR data showing depemokimab improved nasal symptoms, QoL, and cut rescue interventions.

Catch up on new trial readouts, trends in hepatitis B birth dose vaccination, updates in a rare hepatic disease in honor of Rare Disease Day, and more.

In this segment from the latest episode of the Skin of Color Savvy podcast, progress in skin health equity and advancements still needed in 2026 are highlighted.

Isaacs and Bellini discuss recent updates on Eli Lilly's orforglipron and retatrutide and Novo Nordisk's UBT251, along with other recent GLP-1 news.

New research links dietary protein, ammonia buildup, and liver cancer growth, raising questions about targeted nutrition in HCC risk management.

Interim phase 3 APeX-P data presented at AAAAI 2026 show sustained 48-week reductions in moderate and severe HAE attacks with oral berotralstat in children aged 2–11 years.

Catch up with FDA decisions, key trial results, and more.

Parent company United Therapeutics announced ralinepag’s substantial reduction in worsening clinical events, as well as improving 6MWD and NT-proBNP.

Risankizumab achieved superiority for the co-primary and ranked secondary endpoints at week 12 for SC injection versus placebo.

The FDA granted Priority Review and accepted a New Drug Application for rusfertide to treat adults with polycythemia vera.

Neal Bhatia, MD, speaks on new data on ixekizumab and tirzepatide for weight loss and psoriasis, as well as the implications of these data regarding GLP-1 use.

Nguyen discussed how her study findings can help alleviate inhaled corticosteroid hesitancy for families.